Ciwon ƙwayar T-cell mai girma, irin su lymphoma na T-cell ba na Hodgkin ba, suna da haɗari sosai kuma suna da tsayayyar magani, kuma marasa lafiya galibi suna da mummunan hangen nesa. Kwanan nan, “Yanayi” jerin kasidu guda biyu sun buga sabuwar fassarar cutar da ke haifar da kwayar cutar T-cell lymphoma wacce ba ta Hodgkin ba, don haka samar da sabuwar alkibla don ingantaccen ci gaban sabbin hanyoyin kwantar da hankali ga wannan nau’i na cutar ta kwayar cutar.
A cikin binciken farko, ƙungiyar Wartewig ta yi amfani da furotin fusion ITK-SYK don gina tsarin linzamin kwamfuta na transgenic na lymphoma na T-cell na ƙarshe (Nature. Doi: 10.1038 / yanayi24649), kuma sun gano cewa kwafin guda ɗaya ko biyu na PDCD1 Halin da ke ɓoye furotin PD1 an goge shi. T cell lymphoma yana jurewa da sauri m canji kuma yana hanzarta mutuwar ƙirar linzamin kwamfuta. Bugu da ƙari, aikace-aikacen PD1 ko PD-L1 masu hanawa na iya haifar da irin wannan tasiri. Tsarin da ke da alaƙa shine cewa PD1 yana daidaita maganganun PTEN kuma yana hana ƙwayar ƙwayar ƙwayar cuta ta hanyar PI3K.
A cikin wani labarin, Maciocia et al. Aiwatar da chimeric antigen receptor T cell immunotherapy (CAR-T) far (Nat Med. Doi: 10.1038 / nm.4444) don gina sel CAR-T waɗanda ke da niyya musamman TRBC1 amma ba TRBC2 Don magance TRBC1-tabbataccen T-cell carcinoma. Yayin kashe ƙwayoyin tumo, barin isassun ƙwayoyin T don yaƙar kamuwa da cuta. Za a ƙaddamar da gwajin asibiti na wannan hanyar a hukumance a cikin 2018.
Babban editan yanayi Megan Cully ya ce abubuwan da aka ambata da muka ambata a sama sun ba da wata sabuwar dabarar magani don kula da cututtukan T-cell da suka girma kuma suka yi gargadin cewa wadannan ciwace-ciwacen ba su dace da magani tare da masu hana PD1 ko PDL1 ba.
